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In this issue of Critical Care, Robinson and colleagues [1] 
investigate the eﬀ  ect of increasing doses of the low mole-
cu  lar weight (LMW) heparin enoxaparin (commonly 
used as prophylaxis against venous thromboembolism 
(VTE)) on systemic heparin concentrations, expressed as 
anti-factor Xa levels. VTE is a common complication in 
critically ill patients. Reported rates for deep venous 
thrombosis in patients admitted to the ICU range from 
22 to 80% depending on patient characteristics. 
Th   rombo  prophylaxis with unfractionated or LMW 
heparin lowers the risk for deep venous thrombosis by 
more than 50% [2]. Nevertheless, the risk of VTE in 
critically ill patients receiving LMW heparin prophylaxis 
is still much higher than in other patient groups. 
Amongst several factors that may explain the higher 
incidence of VTE in critically ill patients, such as full 
immobilisation or withholding anticoagulant prophylaxis 
because of a high bleeding risk, it was hypothesized that 
limited bioavailability (that is, lower plasma anti-factor 
Xa activity) of subcutaneously administered heparin in 
those patients with impaired peripheral circulation, due 
to vasopressor medication to maintain central blood 
pressure, might be important. Indeed, in a ﬁ  rst 
comparative trial it was shown that critically ill patients 
on high dose vasopressor medication had much lower 
anti-factor Xa concentrations after the subcutaneous 
administration of LMW heparin in comparison with 
intensive care patients that had lower doses of vaso-
pressor or in comparison with patients in the surgical 
ward [3]. A subsequent study also found consistently 
lower anti-factor Xa levels after subcutaneous heparin in 
critically ill patients [4]. In another similar study, critically 
ill patients with excessive subcutaneous oedema had 
lower anti-factor Xa concentrations compared to a 
control group without oedema [5]. Th   is observation was 
conﬁ   rmed in a group of critically ill multiple trauma 
patients, who showed variable and low heparin concen-
trations after subcutaneous injections [6].
Robinson and colleagues [1] compared plasma anti-
factor Xa levels after the subcutaneous administration of 
the LMW heparin enoxaparin at the conventional dose 
(40 mg) and at increasingly higher doses (up to 70 mg) in 
intensive care patients. Th  ey found a dose-dependent 
increase in peak anti-factor Xa levels (4 hours after the 
injection) ranging from 0.13 IU/ml at the conventional 
40 mg dose to 0.29 IU/ml at the 70 mg dose. Considering 
that optimal eﬃ     cacy and safety of LMW heparin for 
thromboprophylaxis in orthopaedic and abdominal 
surgery was achieved with dosages of heparin resulting in 
peak plasma anti-factor Xa activities ranging between 
0.25 and 0.30 IU/ml [7], it may be concluded that 
critically ill patients need much higher doses of LMW 
heparin than other patients. Based on the ﬁ  ndings  of 
Robinson and colleagues, the subcutaneous dose of 
LMW heparin should be increased to 60 mg daily. 
Alternatively, direct intravenous administration of 
(LMW) heparin may be considered; however, experience 
with this type of thromboprophylaxis is limited.
Th  e mechanism by which critically ill patients have 
lower anti-factor Xa levels after subcutaneous adminis-
tration of heparin is not completely understood. Th  e 
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Venous thromboembolism is a relatively frequently 
occurring complication in critically ill patients admitted 
to the ICU despite prophylactic treatment with 
subcutaneous low molecular weight heparin. Several 
studies show that critically ill patients have signifi  cantly 
lower plasma anti-factor-Xa activity levels compared to 
control patients after administration of subcutaneous 
heparin. Robinson and colleagues show in this issue of 
Critical Care dose-dependent but relatively low levels of 
anti-factor Xa activity at increasing doses of enoxaparin. 
Anti-factor Xa levels thought to be required for 
adequate thromboprophylaxis are observed only at 
doses of enoxaparin that are one and a half times 
higher than the conventional dose (40 mg).
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vasopressor medication had impaired subcutaneous 
blood ﬂ   ow and thereby limited ability to adsorb the 
subcutaneous heparin [3]. An alternative explanation is 
that the presence of oedema hinders the absorption of 
heparin, although that hypothesis was not proven [5]. In 
addition, it has been suggested that systemic inﬂ  amma-
tion and associated multiple organ dysfunction may have 
an impact on heparin binding to plasma proteins and 
drug metabolism [8].
Th  e clinical relevance of lower anti-factor Xa levels 
after conventional doses of (LMW) heparin in critically 
ill patients is also not totally clear. Th   eoretically, the low 
anti-factor Xa levels may lead to suboptimal prophylaxis 
and could indeed be a contributory factor to the higher 
incidence of thromboembolic complications in critically 
ill patients despite routine thromboprophylaxis. How-
ever, this has never been demonstrated in a clinical study. 
Based on the observations of Robinson and colleagues 
and others, a randomized controlled trial with con  ven-
tional versus higher doses of thrombosis prophylaxis in 
critically ill patients aiming at the reduction of the 
incidence of VTE and other clinically relevant outcomes 
is justiﬁ  ed. Such a study would also enable the evaluation 
of bleeding complications related to the administration of 
prophylactic heparin, as intensive care patients are at 
higher risk for hemorrhage as well [9,10].
In summary, there is ample evidence that conventional 
thromboprophylaxis leads to lower systemic heparin 
levels in critically ill patients. It is not clear whether this 
contributes to the relatively high incidence of VTE in 
intensive care patients. A clinical trial evaluating higher 
doses of heparin for prevention of VTE and assessing the 
bleeding risk of such an approach is justiﬁ  ed.
Abbreviations
LMW = low molecular weight; VTE = venous thromboembolism.
Competing interests
The author declares that he has no competing interests.
Published: 21 April 2010
References
1.  Robinson S, Zincuk A, Strøm T, Larsen TB, Rasmussen B, Toft P: Enoxaparin, 
eff  ective dosage for intensive care patients: double-blinded, randomised 
clinical trial. Crit Care 2010, 14:R41.
2.  Cook DJ, Crowther MA: Thromboprophylaxis in the intensive care unit: 
focus on medical-surgical patients. Crit Care Med 2010, 38:S76-S82.
3. Dörffl   er-Melly J, de Jonge E, Pont AC, Meijers J, Vroom MB, Büller HR, Levi M: 
Bioavailability of subcutaneous low-molecular-weight heparin to patients 
on vasopressors. Lancet 2002, 359:849-850.
4.  Priglinger U, Delle Karth G, Geppert A, Joukhadar C, Graf S, Berger R, 
Hülsmann M, Spitzauer S, Pabinger I, Heinz G: Prophylactic anticoagulation 
with enoxaparin: Is the subcutaneous route appropriate in the critically ill? 
Crit Care Med 2003, 31:1405-1409.
5.  Rommers MK, Van der Laan N, Egberts TC, van den Bemt PM: Anti-Xa activity 
after subcutaneous administration of dalteparin in ICU patients with and 
without subcutaneous oedema: a pilot study. Crit Care 2006, 10:R93.
6.  Haas CE, Nelsen JL, Raghavendran K, Mihalko W, Beres J, Ma Q, Forrest A: 
Pharmacokinetics and pharmacodynamics of enoxaparin in multiple 
trauma patients. J Trauma 2005, 59:1336-1343; discussion 1343-1344.
7.  Leyvraz PF, Bachmann F, Hoek J, Büller HR, Postel M, Samama M, Vandenbroek 
MD: Prevention of deep vein thrombosis after hip replacement: 
randomised comparison between unfractionated heparin and low 
molecular weight heparin. BMJ 1991, 303:543-548.
8.  Mayr AJ, Dünser M, Jochberger S, Fries D, Klingler A, Joannidis M, Hasibeder 
W, Schobersberger W: Antifactor Xa activity in intensive care patients 
receiving thromboembolic prophylaxis with standard doses of 
enoxaparin. Thromb Res 2002, 105:201-204.
9.  Levi MM, Eerenberg E, Lowenberg E, Kamphuisen PW: Bleeding in patients 
using new anticoagulants or antiplatelet agents: risk factors and 
management. Neth J Med 2010, 68:68-76.
10.  Cook D, Douketis J, Meade M, Guyatt G, Zytaruk N, Granton J, Skrobik Y, Albert 
M, Fowler R, Hebert P, Pagliarello G, Friedrich J, Freitag A, Karachi T, Rabbat C, 
Heels-Ansdell D, Geerts W, Crowther M; Canadian Critical Care Trials Group: 
Venous thromboembolism and bleeding in critically ill patients with 
severe renal insuffi   ciency receiving dalteparin thromboprophylaxis: 
prevalence, incidence and risk factors. Crit Care 2008, 12:R32.
doi:10.1186/cc8949
Cite this article as: Levi M: Adequate thromboprophylaxis in critically ill 
patients. Critical Care 2010, 14:142.
Levi Critical Care 2010, 14:142 
http://ccforum.com/content/14/2/142
Page 2 of 2